Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer

Cell Cycle

Volumn 15, Issue 17, 2016, Pages 2265-2274

  Simone, Brittany A ^a   Dan, Tu ^a   Palagani, Ajay ^a   Jin, Lianjin ^a   Han, Sunny Y ^a   Wright, Christopher ^a   Savage, Jason E ^b   Gitman, Robert ^a   Lim, Meng Kieng ^a   Palazzo, Juan ^a   Mehta, Minesh P ^c   Simone, Nicole L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MIAMI CANCER INSTITUTE   (United States)

Author keywords

breast cancer; Caloric restriction; metastases

Indexed keywords

LUCIFERASE; SOMATOMEDIN C RECEPTOR; PROTEIN KINASE B; SOMATOMEDIN C; TISSUE EXTRACT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CALORIC RESTRICTION; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; INTRACELLULAR SIGNALING; LUNG METASTASIS; MOLECULAR IMAGING; MOUSE; MOUSE MODEL; MULTIMODALITY CANCER THERAPY; NONHUMAN; OVERALL SURVIVAL; PRIMARY TUMOR; RECEPTOR DOWN REGULATION; SYSTEMIC THERAPY; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; HUMAN; IONIZING RADIATION; LUMINESCENCE; LUNG; LUNG TUMOR; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANIMALS; APOPTOSIS; CALORIC RESTRICTION; CELL PROLIFERATION; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LUMINESCENT MEASUREMENTS; LUNG; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, INBRED BALB C; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION, IONIZING; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TISSUE EXTRACTS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84980390540     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2016.1160982     Document Type: Article

References (41)

1. R.Siegel, D.Naishadham, A.Jemal. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30; PMID:23335087
2. M.Smid, Y.Wang, Y.Zhang, A.M.Sieuwerts, J.Yu, J.G.Klijn, J.A.Foekens, J.W.Martens. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008; 68:3108-14; PMID:18451135; http://dx.doi.org/10.1158/0008-5472.CAN-07-5644
3. N.U.Lin, E.Claus, J.Sohl, A.R.Razzak, A.Arnaout, E.P.Winer. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer:high incidence of central nervous system metastases. Cancer 2008; 113:2638-45; PMID:18833576; http://dx.doi.org/10.1002/cncr.23930
4. S.M.Swain, J.Baselga, S.B.Kim, J.Ro, V.Semiglazov, M.Campone, E.Ciruelos, J.M.Ferrero, A.Schneeweiss, S.Heeson, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372:724-34; PMID:25693012; http://dx.doi.org/10.1056/NEJMoa1413513
5. C.A.Hudis, L.Gianni. Triple-negative breast cancer:an unmet medical need. Oncologist 2011; 16 Suppl 1:1-11; PMID:21278435; http://dx.doi.org/10.1634/theoncologist.2011-S1-01
6. B.D.Lehmann, J.A.Bauer, X.Chen, M.E.Sanders, A.B.Chakravarthy, Y.Shyr, J.A.Pietenpol. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-67; PMID:21633166; http://dx.doi.org/10.1172/JCI45014
7. N.J.Robert, V.Dieras, J.Glaspy, A.M.Brufsky, I.Bondarenko, O.N.Lipatov, E.A.Perez, D.A.Yardley, S.Y.Chan, X.Zhou, et al. RIBBON-1:randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29:1252-60; PMID:21383283; http://dx.doi.org/10.1200/JCO.2010.28.0982
8. J.Wang, T.Sinnberg, H.Niessner, R.Dolker, B.Sauer, W.E.Kempf, F.Meier, N.Leslie, B.Schittek. PTEN regulates IGF-1R-mediated therapy resistance in melanoma. Pigment Cell Melanoma Res 2015; 28:572-89; PMID:26112748; http://dx.doi.org/10.1111/pcmr.12390
9. N.Dey, C.Williams, B.Leyland-Jones, P.De. A critical role for HER3 in HER2-amplified and non-amplified breast cancers:function of a kinase-dead RTK. Am J Transl Res 2015; 7:733-50; PMID:26064441
10. M.S.De Lorenzo, E.Baljinnyam, D.E.Vatner, P.Abarzua, S.F.Vatner, A.B.Rabson. Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis 2011; 32:1381-7; PMID:21665891; http://dx.doi.org/10.1093/carcin/bgr107
11. W.C.Buschemeyer, 3rd, J.C.Klink, J.C.Mavropoulos, S.H.Poulton, W.Demark-Wahnefried, S.D.Hursting, P.Cohen, D.Hwang, T.L.Johnson, S.J.Freedland. Effect of intermittent fasting with or without caloric restriction on prostate cancer growth and survival in SCID mice. Prostate 2010; 70:1037-43; PMID:20166128; http://dx.doi.org/10.1002/pros.21136
12. A.D.Saleh, B.A.Simone, J.Palazzo, J.E.Savage, Y.Sano, T.Dan, L.Jin, C.Champ, S.Zhao, M.Lim, et al. Caloric restriction augments radiation efficacy in breast cancer. Cell Cycle 2013; 12:1955-63; PMID:23708519; http://dx.doi.org/10.4161/cc.25016
13. R.Dent, M.Trudeau, K.I.Pritchard, W.M.Hanna, H.K.Kahn, C.A.Sawka, L.A.Lickley, E.Rawlinson, P.Sun, S.A.Narod. Triple-negative breast cancer:clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429-34; PMID:17671126; http://dx.doi.org/10.1158/1078-0432.CCR-06-3045
14. C.Bahr, B.Groner. The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors 2005; 23:1-14; PMID:16019422; http://dx.doi.org/10.1080/08977190400020229
15. J.Qian, A.Dong, M.Kong, Z.Ma, J.Fan, G.Jiang. Suppression of type 1 Insulin-like growth factor receptor expression by small interfering RNA inhibits A549 human lung cancer cell invasion in vitro and metastasis in xenograft nude mice. Acta Biochim Biophys Sin (Shanghai) 2007; 39:137-47; PMID:17277889; http://dx.doi.org/10.1111/j.1745-7270.2007.00257.x
16. M.Gryko, J.Kisluk, D.Cepowicz, J.Zinczuk, Z.Kamocki, K.Guzinska-Ustymowicz, A.Pryczynicz, J.Czyzewska, A.Kemona, B.Kedra. Expression of insulin-like growth factor receptor type 1 correlate with lymphatic metastases in human gastric cancer. Pol J Pathol 2014; 65:135-40; PMID:25119174; http://dx.doi.org/10.5114/pjp.2014.42678
17. M.J.Bonorden, O.P.Rogozina, C.M.Kluczny, M.E.Grossmann, J.P.Grande, A.Lokshin, M.P.Cleary. Cross-sectional analysis of intermittent vs. chronic caloric restriction in the TRAMP mouse. Prostate 2009; 69:317-26; PMID:19016490; http://dx.doi.org/10.1002/pros.20878
18. M.P.Cleary, M.K.Jacobson, F.C.Phillips, S.C.Getzin, J.P.Grande, N.J.Maihle. Weight-cycling decreases incidence and increases latency of mammary tumors to a greater extent than does chronic caloric restriction in mouse mammary tumor virus-transforming growth factor-α female mice. Cancer Epidemiol Biomarkers Prev 2002; 11:836-43.
19. W.B.Ershler, E.Berman, A.L.Moore. Slower B16 melanoma growth but greater pulmonary colonization in calorie-restricted mice. J Natl Cancer Inst 1986; 76:81-5; PMID:3455745
20. C.Lee, V.D.Longo. Fasting vs dietary restriction in cellular protection and cancer treatment:from model organisms to patients. Oncogene 2011; 30:3305-16; PMID:21516129; http://dx.doi.org/10.1038/onc.2011.91
21. C.Lee, F.M.Safdie, L.Raffaghello, M.Wei, F.Madia, E.Parrella, D.Hwang, P.Cohen, G.Bianchi, V.D.Longo. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res 2010; 70:1564-72; PMID:20145127; http://dx.doi.org/10.1158/0008-5472.CAN-09-3228
22. V.D.Longo, L.Fontana. Calorie restriction and cancer prevention:metabolic and molecular mechanisms. Trends Pharmacol Sci 2010; 31:89-98; PMID:20097433; http://dx.doi.org/10.1016/j.tips.2009.11.004
23. R.Baserga, A.Hongo, M.Rubini, M.Prisco, B.Valentinis. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1997; 1332:F105-26; PMID:9196021
24. D.Metalli, F.Lovat, F.Tripodi, M.Genua, S.Q.Xu, M.Spinelli, L.Alberghina, M.Vanoni, R.Baffa, L.G.Gomella, et al. The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol 2010; 176:2997-3006; PMID:20395438; http://dx.doi.org/10.2353/ajpath.2010.090904
25. Y.Wang, Q.S.Ji, M.Mulvihill, J.A.Pachter. Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches. Recent Results Cancer Res 2007; 172:59-76; PMID:17607936; http://dx.doi.org/10.1007/978-3-540-31209-3_5
26. S.J.Shin, G.Gong, H.J.Lee, J.Kang, Y.K.Bae, A.Lee, E.Y.Cho, J.S.Lee, K.S.Suh, D.W.Lee, et al. Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancer. J Breast Cancer 2014; 17:113-20; PMID:25013431; http://dx.doi.org/10.4048/jbc.2014.17.2.113
27. A.V.Lee, J.G.Jackson, J.L.Gooch, S.G.Hilsenbeck, E.Coronado-Heinsohn, C.K.Osborne, D.Yee. Enhancement of insulin-like growth factor signaling in human breast cancer:estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 1999; 13:787-96; PMID:10319328; http://dx.doi.org/10.1210/mend.13.5.0274
28. Z.Davison, G.E.de Blacquiere, B.R.Westley, F.E.May. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells:implications for therapy. Neoplasia 2011; 13:504-15; PMID:21677874; http://dx.doi.org/10.1593/neo.101590
29. P.Haluska, H.M.Shaw, G.N.Batzel, D.Yin, J.R.Molina, L.R.Molife, T.A.Yap, M.L.Roberts, A.Sharma, A.Gualberto, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13:5834-40; PMID:17908976; http://dx.doi.org/10.1158/1078-0432.CCR-07-1118
30. J.C.Soria, C.Massard, V.Lazar, M.L.Ozoux, D.Mery-Mignard, A.Deslandes, A.W.Tolcher. A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours. Eur J Cancer 2013; 49:1799-807; PMID:23485230; http://dx.doi.org/10.1016/j.ejca.2013.01.003
31. H.X.Chen, E.Sharon. IGF-1R as an anti-cancer target–trials and tribulations. Chinese J Cancer 2013; 32:242-52; PMID:23601239; http://dx.doi.org/10.5732/cjc.012.10263
32. M.L.Hixon, L.Paccagnella, R.Millham, R.Perez-Olle, A.Gualberto. Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway. Rev Recent Clin Trials 2010; 5:189-208; PMID:20533896; http://dx.doi.org/10.2174/157488710792007329
33. F.Meriggi. Cancer Cachexia:One Step Ahead. Rev Recent Clin Trials 2015; 10:246-50; PMID:26435290; http://dx.doi.org/10.2174/1574887110666150916141351
34. B.A.Simone, C.E.Champ, A.L.Rosenberg, A.C.Berger, D.A.Monti, A.P.Dicker, N.L.Simone. Selectively starving cancer cells through dietary manipulation:methods and clinical implications. Future Oncol 2013; 9:959-76; PMID:23837760; http://dx.doi.org/10.2217/fon.13.31
35. R.K.Mittapalli, S.Vaidhyanathan, A.Z.Dudek, W.F.Elmquist. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain:implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther 2013; 344:655-64; PMID:23249624; http://dx.doi.org/10.1124/jpet.112.201475
36. A.Alonso. Ultrasound-induced blood-brain barrier opening for drug delivery. Front Neurol Neurosci 2015; 36:106-15; PMID:25531667; http://dx.doi.org/10.1159/000366242
37. I.J.Barani, D.A.Larson, M.S.Berger. Future directions in treatment of brain metastases. Surg Neurol Int 2013; 4:S220-30; PMID:23717793
38. C.A.Schneider, W.S.Rasband, K.W.Eliceiri. NIH Image to ImageJ:25 years of image analysis. Nat Methods 2012; 9:671-5; PMID:22930834; http://dx.doi.org/10.1038/nmeth.2089
39. J.D.Martina, C.Simmons, D.M.Jukic. High-definition hematoxylin and eosin staining in a transition to digital pathology. J Pathol Inform 2011; 2:45; PMID:22059146; http://dx.doi.org/10.4103/2153-3539.86284
40. J.M.Carboni, M.Wittman, Z.Yang, F.Lee, A.Greer, W.Hurlburt, S.Hillerman, C.Cao, G.H.Cantor, J.Dell-John, et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 2009; 8:3341-9; PMID:19996272; http://dx.doi.org/10.1158/1535-7163.MCT-09-0499
41. J.B.Mitchell, R.Choudhuri, K.Fabre, A.L.Sowers, D.Citrin, S.D.Zabludoff, J.A.Cook. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010; 16:2076-84; PMID:20233881; http://dx.doi.org/10.1158/1078-0432.CCR-09-3277